# Christophe Ricard

> Christophe Ricard is a seed investor backing Life Science and Biotechnology. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Location: Geneva, Switzerland
- Total investments: 2
- Last investment: Dec 2023
- Lead investor: 0%
- Last updated: Aug 2026

Christophe Ricard is a seed investor in Geneva focused on Life Science and Biotechnology. Christophe Ricard CEO of OM Pharma

## Contacts

5 contacts available for Christophe Ricard: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/christophe-ricard-889a?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 1 | 50% |
| Biotechnology | 1 | 50% |
| Medical Device | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series B | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Antabio | Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France. | $27M | Series B | Dec 12, 2023 |  |
| Antabio | Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. Thecompany's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France. |  | Seed | Jan 12, 2012 |  |

2 of 2 investments shown.

## Co-investors
- [AMR Action Fund](https://shizune.co/investors/profile/amr-action-fund) — VC Fund, 1 deal together
- [BNP Paribas Développement](https://shizune.co/investors/profile/bnp-paribas-developpement) — VC Fund, 1 deal together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 1 deal together
- [IRDI SORIDEC Gestion](https://shizune.co/investors/profile/irdi-soridec-gestion) — VC Fund, 1 deal together
- [Turenne Capital](https://shizune.co/investors/profile/turenne-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [Kima Ventures](https://shizune.co/investors/profile/kima-ventures) — VC Fund
- [Motier Ventures](https://shizune.co/investors/profile/motier-ventures) — VC Fund

## Featured in investor lists
- [Medical Device Angel Investors in France](https://shizune.co/investors/medical-device-angel-investors-france)
- [Biotechnology Angel Investors in France](https://shizune.co/investors/biotechnology-angel-investors-france)
- [Biotech Angel Investors in France](https://shizune.co/investors/biotech-angel-investors-france)
- [Life Science Angel Investors in Europe](https://shizune.co/investors/life-science-angel-investors-europe)
- [Life Science Investors in France](https://shizune.co/investors/life-science-investors-france)

## FAQ

### What does Christophe Ricard invest in?

Christophe Ricard invests primarily in Life Science, Biotechnology and Medical Device startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Christophe Ricard?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Christophe Ricard last invest?

The most recent investment recorded for Christophe Ricard closed in Dec 2023. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co